Nasdaq atai.

Instrument Name Atai Life Sciences N.V. Instrument Symbol (ATAI-Q). Instrument Exchange NASDAQ ; Previous Close 1.1200 ; 52-Week High/Low 3.6500 1.0400 ; Volume ...NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ...NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to ...He was also CFO of atai Life Sciences (Nasdaq: ATAI), completing over $282M in late-stage private financings and led a successful $258M IPO at a $2.3B valuation to support the acquisition of ...Nov 30, 2023 · Atai Life Sciences Announces Results from the Phase 1 Iv-To-Subcutaneous Bridging Study of Pcn-101 (R-Ketamine) Aug. 08: CI Atai Life Sciences N.V., Atai Life Sciences AG Enters into the Second Amendment to Loan and Security Agreement with the Several Banks May. 31: CI

Short Interest. Many investors believe that rising short interest positions in a stock is a bearish indicator. They use the Days to Cover statistic as a way to judge rising or falling sentiment in ...Topline results are expected in the first half of 2024. NEW YORK and BERLIN, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage ...NEW YORK, Dec. 16, 2020 /PRNewswire/ -- atai Life Sciences ('atai' or the 'Company'), a global biotech company developing psychedelic and non-psyc... NEW YORK, Dec. 16, 2020 /PRNewswire/ -- atai Life Sciences ("atai" or the "Company"), a gl...

NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to ...3. Psychedelics Stocks Rise In First Post-Tax Loss Selling Week. The psychedelic sector rose moderately in the first week of 2023 past week, as reflected by the Horizon Psychedelic Stock Index (PSYK) ETF ↑4.70%.Despite a negative readout for atai Life Sciences compound PCN-101, the market ended higher and sharply outperformed …

I’ve also been asked if it’s proper and ethical that COMPASS Pathways (Nasdaq: CMPS) and atai Life Sciences (Nasdaq: ATAI) own the majority of the patents around those psychedelics.NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R …Let’s get straight to it: The psychedelic stock market continues to underperform. Taking a look at our Psychedelic Invest Index, we can see that only two companies that trade for a greater than $50 million market cap were up in the month of November: atai Life Sciences (ATAI) & GH Research (GHRS). Wait, there are...The fund has raised an initial $35 million in capital and currently holds an active portfolio of 20 companies, including investments in Atai Life Sciences (NASDAQ: ATAI), Reset Pharma, Field Trip ...Short Interest. Many investors believe that rising short interest positions in a stock is a bearish indicator. They use the Days to Cover statistic as a way to judge rising or falling sentiment in ...

NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has been dosed in Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN ...

Atai Life Sciences (NASDAQ:ATAI) has a recorded annual revenue of $230,000.00. How much profit does Atai Life Sciences generate each year? Atai Life Sciences (NASDAQ:ATAI) has a recorded net income of -$152.38 million.

Over the past 3 months, 7 analysts have published their opinion on ATAI Life Sciences (NASDAQ:ATAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...Atai Life Sciences (NASDAQ: ATAI) focuses on therapeutics to treat mental health issues, such as anxiety, depression or addiction. This clinical-stage biopharma company went public in June 2021.Aug 2, 2023 · As of August 2, 2023, the average one-year price target for ATAI Life Sciences N.V. is 12.51. The forecasts range from a low of 5.15 to a high of $22.05. The average price target represents an ... The average trading volume of ATAI on November 29, 2023 was 536.92K shares. ATAI) stock’s latest price update. The stock price of ATAI Life Sciences N.V. (NASDAQ: ATAI) has plunged by -3.51 when compared to previous closing price of 1.14, but the company has seen a 2.80% gain in its stock price over the last five trading sessions.Alcohol use disorder. Treatment-resistant depression. Opiate withdrawal syndrome. PTSD. Social anxiety in autistic adults. Anxiety with a life-threatening illness. Generalized anxiety disorder ...Aug 2, 2023 · As of August 2, 2023, the average one-year price target for ATAI Life Sciences N.V. is 12.51. The forecasts range from a low of 5.15 to a high of $22.05. The average price target represents an ...

Atai Life Sciences (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company transforming the treatment of mental health disorders. On January 12, ...Over the past 3 months, 7 analysts have published their opinion on ATAI Life Sciences (NASDAQ:ATAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...Oct 31, 2023 · Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Investors In Q2 2023: 7 Atai Life Sciences N.V. (NASDAQ:ATAI) is a biotechnology company developing treatments for mental health disorders. October 6, 2023. NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inau... atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy ...Analyst's Opinion · Consensus Rating. Atai Life Sciences has received a consensus rating of Buy. · Price Target Upside/Downside. According to analysts' ...

RedHill Biopharma Ltd. (NASDAQ:RDHL) said Medi-Cal - California's Medicaid Health Care program covering two million patients - has added its Talicia to its contract drug list for H. pylori ...

NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental health ...NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...NEW YORK and BERLIN, Oct. 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...Nov 29, 2021 · NEW YORK, Nov. 29, 2021-- atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it has increased its ... Nov 29, 2023 · The average trading volume of ATAI on November 29, 2023 was 536.92K shares. ATAI) stock’s latest price update. The stock price of ATAI Life Sciences N.V. (NASDAQ: ATAI) has plunged by -3.51 when compared to previous closing price of 1.14, but the company has seen a 2.80% gain in its stock price over the last five trading sessions. (RTTNews) - atai Life Sciences N.V. (ATAI) reported additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. KUR-101 was well tolerated and showed ...Nov 30, 2023 · Atai Life Sciences Announces Results from the Phase 1 Iv-To-Subcutaneous Bridging Study of Pcn-101 (R-Ketamine) Aug. 08: CI Atai Life Sciences N.V., Atai Life Sciences AG Enters into the Second Amendment to Loan and Security Agreement with the Several Banks May. 31: CI

NL0015000DX5. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany. Show more.

Oct 2, 2023 · 3:24 pm. Articles. atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) August 10, 2023 Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients…. August 10, 2023.

The financial services firm H.C. Wainwright & Co. recently issued a $20 price target on ATAI Life Sciences (ATAI 7.69%) stock. This 12-month price target implies an upside potential of 969% from ...3:24 pm. Articles. atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) August 10, 2023 Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients…. August 10, 2023.NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...NEW YORK and BERLIN, Sept. 27, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), which is developing EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for ...ATAI Life Sciences Stock (NASDAQ:ATAI), Guidance and Forecast benzinga.com - August 13 at 4:19 AM: ATAI Life Sciences Stock (NASDAQ:ATAI), Short Interest Report benzinga.com - August 12 at 11:19 PM: ATAI Life Sciences (ATAI) Receives a Buy from Berenberg Bank markets.businessinsider.com - August 11 at 5:09 PMNEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to …atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October 11-12, 2023.With a Buy rating, Roth Capital initiated coverage on ATAI Life Sciences NV (NASDAQ:ATAI). The price target seems to have been set at $32.00 for ATAI Life Sciences. In the second quarter, ATAI ...Through its subsidiary Perception Neuroscience, atai Life Sciences N.V. (NASDAQ:ATAI) recently released an update on another platform for treatment resistant depression (TRD) ...

ATAI Life Sciences (NASDAQ: ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders. The company has recently garnered ...Real time Atai Life Sciences (ATAI) stock price quote, stock graph, news & analysis.Back to ATAI Overview. Get up to 10 years of daily historical stock prices & volumes. Data provided by Edgar Online. ©2021, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is ...Instagram:https://instagram. american fund europacific growth r6stock option nytzynerba pharmaceuticals stockbest stock websites Oct 5, 2022 · - atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023. - VLS-01 is a synthetic form of N,N-dimethyltryptamine ... Jul 16, 2021 ... ATAI Life Sciences N.V.(Nasdaq:ATAI): ATAI Life Sciences N.V (ATAI), Compass Pathways Plc (CMPS), and Mind Medicine Holdings (MNMD) are 3 ... everspruce appbest demo forex account NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor events & healthcare conferences: Financial Times Pharma and Biotech Summit in Londonatai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021. forex brokers usa metatrader 4 NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...Atai Life Sciences’ (NASDAQ: ATAI) stock fell more than 40% after the primary endpoint of a phase 2a clinical trial examining the use of ketamine treatment to treat depression was not met.